Methods currently used for immunofluorescent (IF) reagent standardization require subjective comparison of reagents with control materials. Although this is a widespread and satisfactory use in IF reagent testing, certain problems arise that can be solved by the use of a quantitative measurement system for endpoint determination. Drifting reactivities of the fluorochrome-conjugated antibody could result in conjugates with diminished abilities to distinguish positive specimens from negative specimens. Reliance of a reader on memory causes the endpoint to be based on a recollection of the brightness of the reading standard, resulting in the grouping of intensities classified as negative or positive (1 + to 4+) rather than the assignment of a certain value. The variability associated with a subjective, visually determined endpoint results from factors such as retinal sensitivity, personal biases, and variability due to the instrument and microscope system (i.e., filter quality, the exciting lamp, and its focusing, age, and alignment).
In an effort to improve the quality of diagnostic reagents, the Centers for Disease Control offered a voluntary reagents evaluation program. This program, which has been abolished, allowed manufacturers to submit some of their products for testing before marketing them. The current lack of such a voluntary program again stresses the importance of developing a quantitative measurement system for endpoint determination. Durham and Colvin (2) tested 112 products from seven manufacturers of commercial toxoplasmosis indirect fluorescent-antibody reagents. Among the several problems with the kits were over-or undersensitivity of the anti-human fluorescein isothiocyanate (FITC) conjugate and over-or underreactivity of positive control sera.
In order to remove subjectivity from these tests, we developed a microphotometric system for the quantification of IF from tagged cells-bacterial, protozoan, and mammalian-by using a microscope-photometer capable of measur-* Corresponding author.
ing the fluorescence intensity of individual organisms (6) . This quantitative immunofluorescence (QIF) method is applicable to both direct-and indirect-IF systems. The fluorescence intensity is proportional to the amount of tagged antigen-antibody complex on the IF microscopy slide, which, in turn, is proportional to the antibody concentration in the test serum (i.e., the patient's serum). For antibodies to toxoplasmosis, the endpoint or titer is defined as the highest dilution in which most of the organisms show weakly visible fluorescence around the entire periphery of the cell. Since the reaction on the IF slide occurs in the dilution range in which proportionality between constituents occurs, the quantitative fluorescence intensity can be used as an indicator of the titer and the consistency of the constituents, which are important in quality control. Thus, dependence on subjective estimates of reactivity (reported as negative to 4+) will be eliminated. Lesko each dilution of the negative control was subtracted from the three corrected intensity values at the corresponding dilution of the sera positive for T. gondii antibodies. These values represented the true corrected intensity, less background and nonspecific staining. These three values were averaged to obtain the mean corrected intensity at each dilution.
RESULTS
The effect of DTE in the mounting medium on the visually determined titer is shown in Table 1 . The change in titer was defined as the difference in the number'of twofold dilutions for each sample read with and without DTE in the mounting medium. When observed by observer 1, 60% of the time the titer was the same both with and without DTE and in no case did the titer differ by more than one twofold dilution. When observed by D. S. Kaplan, about 44% of the time the titers were raised by one twofold dilution and only 4% of the time was the titer raised by two twofold dilutions.
The agreement in visual titer determinations on each of the sera positive for T. gondii antibodies for each reader (observer 1 and observer 2) versus (arbitrarily chosen) determinations for Kaplan is shown in Table 2 . The number of twofold dilutions by which the titer changed is the difference between Kaplan's visually determined titer and the other readers' visually determined titer. For the samples read with DTE present in the mounting medium, no reader's titer differed by more than one twofold dilution from that determined by the other readers. Without DTE, however, 6% of the titers were outside the range plus or minus one twofold dilution.
The quantitatively determined titer was compared with the visually obtained titer (by using specimens read with DTE present by observer 1) for each of 62 specimens by using the established r = 0.94 cutoff to determine the titer (Fig. 2) . The results were identical for 41 specimens, differéd by plus or minus one twofold dilution for 17 specimens, differed by plus or minus two twofold dilutions for 3 specimens, and differed by plus or minus three twofold dilutions for 1 specimen. The correlation coefficient, r, was determined to be 0.9433; the standard error of the visual method estimate (y) was 0.7957, and r2 was 0.8899. The equation for the linear regression line was as follows: visual method estimate (y) = 1.0066 x QIF method (x) -0.5548.
All of the specimens for which the quantitatively determined titer was the same dilution were plotted, showing the net mean corrected intensity versus the log2 dilution. Figure  3 is a representative titer curve showing the 1:128 titer group of 36 specimens read in the presence of DTE. Similar data were obtained in the absence of DTE. These data were analyzed by linear regression analysis, excluding the dilutions with values beyond that of the cutoff dilution, as established by the r = 0.94 cutoff. The linear regression line is shown on the plot. The r values 'for the correlation between the mean corrected intensity and the log2 of the dilution are shown in Table 3 . This analysis showed that the fluorescence intensity was correlated with the antibody concentration in the serum, as long as the dilutions were in the linear range for intensity measurements.
The linear regression statistics were compared for the specimens for which the quantitatively determined titer was the same dilution. The intensity readings for each sample were normalized against the highest initial intensity reading for that sample in order to have all the starting intensities equivalent and to compensate for the different antibody concentrations among the sera. The slopes of the regression lines for each specimen within a group for which the quantitative titer was the same dilution were found to be the same. A parallelism test (4) on the slopes in each group for which the quantitative titer was the same dilution showed that a common slope (m = -0.36) could be used to characterize the relationship between the mean corrected intensity and the log2 dilution, since the hypothesis of a common slope was not rejected at the 95% significance level. These results showed that the intensity is proportional to the antibody concentration for the titer groups tested. Although the slopes were parallel for each titer group, the hypothesis of a common y intercept must be rejected. The rejection was based on a linearity test (4), with P = 0.0312. When the y intercepts (mean corrected intensity) for each of the groups for which the quantitative titer was the same dilution were calculated on the basis of the common slope, a titer-dependent rise in the intercepts was shown (Fig. 4) , illustrating that the endpoint changes in each titer group. This expected result was a function of the method used for analyzing the titer data. The regression line in each group is described by the following equation: mean corrected intensity = y intercept -0.36 x log2 of the dilution. On the basis of the regularity of the regression lines, the quantitative method is a consistent means of determining a titer.
The intensities of positive sera at their endpoint dilutions were compared. A plot of the mean corrected intensity at the endpoint dilution versus the log2 of the endpoint dilution is shown in Fig. 5 ; all sera used were those with intensities measured in the presence of DTE. Similar data were ob- tained by using all the sera that were measured without DTE. Note that this graph contains data from both manufacturers' toxoplasmosis IF kits measured (ENI and MBR). Also shown is the grand mean corrected intensity at the titer and the grand mean intensity + 2 SD. Analysis of the intensities, at the endpoint dilution (Fig. 5) , of the sera By using the information in Fig. 5 and Table 4 , an intensity range which included the mean titer intensity + 2 SD was selected as the titer intensity range. Whenever the measured intensity within a dilution fell within this titer intensity range, that dilution was chosen as the titer. The fluorescence of sera negative for T. gondii antibodies was measured (in the presence of DTE) to compare the intensity of the positive sera, at the endpoint dilution, with that of the negative sera, at a 1:16 dilution. A mean intensity of 0.0556 with an SD of 0.0197 was obtained for the sera negative for T. gondii antibodies. A range of 0.02 to 0.09 resulted from including the mean intensity ± 2 SD. Figure 6 shows a plot of the mean corrected intensity for each negative serum (with the mean intensity of the 1:16 negative control subtracted) versus individual negative serum. A similar intensity range was found for sera negative for T. gondii antibodies measured without DTE present. *.
---2SD (14) .
In the QIF method, as shown in Tables 1 and 2 , the presence of DTE allowed better agreement among the readers, producing a smaller spread in the range of the difference in titer as well as a high percentage of "no change" readings. Since the initial intensity with DTE present is up to 10 times greater than the unprotected intensity (9), mounting specimens with DTE allows the visualization of the initial, unfaded intensity and the discrimination of weakly positive specimens from truly negative specimens.
Considering the samples read with DTE, the correlation (r) between the visual and QIF methods was high, 0.9433. The fact that r2 is 0.89 says that 89% of the variance in the QIF results is explained by the variance in the visual results. Since ±1 twofold dilution is considered the reproducibility range for these types of tests, only 4 of 62 specimens did not show agreement. Thus, this 94% agreement validates the usefulness of the QIF technique.
The quantitatively determined intensity range at the endpoint dilution (-0.05 to 0.22) was the same by using both ENI and MBR kits, verifying that the kit components are calibrated so that the positive controls produce an intensity equivalent to the titer intensity range when the controls are diluted to a previously determined dilution range. This suggests that the method for quantitatively determining titers should be applicable to a variety of manufacturers' test kits and not be limited to the kit from which the measuring parameters were optimized.
When searching for the proper negative control to use in the toxoplasmosis IF kit, two points should be noted. (i) Sera diluted less than 1:128 and negative for T. gondii antibodies may exhibit polar fluorescence (fluorescence at one or both ends of the cells, but not around the entire periphery of the cells, as would occur in a positive reaction) (12, 13) . (ii) The polar staining is usually eliminated by using serum more dilute than 1:128. Subtracting the intensity of the negative control (at dilutions in which polar fluorescence is normally exhibited) from the intensity of the test sera (at dilutions in which polar fluorescence usually is not visible) resulted in intensity measurements that were less than zero. This occurred because the control contained a fluorescence intensity component (polar fluorescence) which was not present in the test serum, and therefore, the negative control was more intense than the test serum. However, when the intensity of that dilution of the negative control that corresponded to the same dilution of the specimen was subtracted, those samples with intensity values initially less than zero by this method were corrected to zero.
Subtracting the intensity of the negative control, at a 1:16 dilution, from the grand mean intensity of the sera negative for T. gondii antibodies led to the establishment of a baseline, nonspecific intensity due to several causes (i.e., impure antigen, cross-reacting antibody, incomplete washing of serum or conjugate, method of fixing antigen to slide, etc.). This low-level fluorescence intensity (0.05 Corning unit) is a component of all the intensities measured and does not disappear upon dilution. However, since this baseline fluo-rescence is also a component of the negative control intensity, this nonspecific component is removed from the intensity of the sera positive for T. gondii antibodies when the proper negative control intensity is subtracted.
The mean intensity of the positive sera (0.09 Corning unit) at the endpoint dilution is above the level of nonspecific fluorescence, although the range of intensities of the negative sera and the positive sera overlap. This overlap is the result of the variability in the antibody concentration in each serum. It occurs because of the method of preparing dilutions in the IF test, as specified in the current guidelines. The Centers for Disease Control recommends that patient specimens be tested in fourfold dilutions, which means that the increment between consecutive dilutions increases exponentially as the dilution factor increases. As a result, depending on the antibody concentration in the serum, after only one fourfold dilution the antibody concentration could be reduced such that the emitted intensity of the labeled cells is at the lower limit of the titer intensity range. The differences in antibody concentration in each serum were compensated for partially by normalizing the intensities against the highest intensity for that sample. Additionally, the intensity of the negative control could be artificially elevated owing to cross-reacting antibodies such as antinuclear antibodies (1) or to the presence of fluorescing debris.
Since the linear regression parameters (common slope and endpoint dilution-dependent y intercepts) are known for each group for which the quantitative titer was the same dilution, it is possible to extrapolate the intensity to the titer intensity range by using any three consecutive twofold dilutions that show a linear relationship between the mean corrected intensity and the log2 dilution. This extrapolation is valid as long as the intensity values are below the range in which the PMT is saturated and above the background intensity. This modification would reduce the time required to determine a quantitative titer, since it is necessary only to measure the intensity from three dilution wells. Estimation of the titer by using dilutions in which the intensity is above the titer intensity range would permit more accurate determination of quantitative titers by eliminating interference due to fluorescing debris and electronic noise at the endpoint dilution. In addition, the intensities from dilutions above the endpoint dilution would be greater than the background fluorescence such that a small fluctuation in the negative control intensity would not alter the quantitative titer.
The parallel slopes for each of the titer groups and the correlation of the endpoint of the quantitative titer between two different manufacturers (ENI and MBR) suggest that the technique may be applicable to other manufacturers' toxoplasmosis IF kits.
In summary, the QIF technique shows a 94% correlation and a 94% agreement with the visual method of determining titers (Fig. 2) . It has thus been demonstrated that it could reliably replace the subjective, visual method of endpoint determination. The QIF technique would eliminate retesting the sera to accommodate the variability and uncertainty associated with visually determined titers. The occurrence of false-positive and false-negative reactions should decrease. This technique permits daily and interlaboratory comparisons of intensity values and quality control in the manufacture of reagents and kits.
